Abbott Laboratories (ABT)
Abbott Laboratories (ABT) carries a ŷRobot AI score of 48 out of 100. The model's fair value estimate is $97.97, 6.6% below the last close of $104.88. The chart signal reads Bullish.
| Metric | ABT |
|---|---|
| AI score | 48 / 100 |
| Chart signal | Bullish |
| Fair value estimate | $97.97 |
| Upside to fair value | -6.6% |
| Previous close | $104.88 |
| P/E | 32.73 |
| Price / sales | 3.59 |
| Market cap | $178.18B |
| EPS | 3.02 |
| Revenue growth | 0.9% |
| 1-year price change | 3.2% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, UnitedHealth Group Incorporated, Merck & Company Inc, Novartis AG ADR.
Questions about ABT
Is ABT overvalued or undervalued right now?
As of Oct 16, 2026, ŷRobot's fair-value model estimates Abbott Laboratories (ABT) at $97.97 against a last close of $104.88, implying 6.6% downside to the model's estimate.
Is ABT's chart signal bullish or bearish?
The chart-signal model classifies ABT as Neutral as of Oct 16, 2026, with a signal score of 0.13 on a -1 to 1 scale.
What is ABT's ŷRobot AI score?
ABT scores 48 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 16, 2026.
Is ABT stock expensive on P/E and P/S?
ABT trades at 32.7 times earnings and 3.6 times sales as of Oct 16, 2026.
What does ABT's seasonal forecast show?
ŷRobot's seasonal forecast curve for ABT reads +0.6% at 30 days, +3.9% at 90 days, and +3.2% at one year as of Oct 16, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is ABT growing?
Abbott Laboratories's revenue growth is +0.9% and free-cash-flow growth is -2.4% on the latest reported figures.
ABT chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.